CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2999
-0.0140 (-4.47%)
Aug 29, 2025, 3:58 PM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
376.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2025 | - | - | - |
May 31, 2024 | - | - | - |
May 31, 2023 | - | - | - |
May 31, 2022 | 266.00K | - | - |
May 31, 2021 | - | - | - |
May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
CytoDyn News
- 4 days ago - CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - CytoDyn files $100M mixed securities shelf - Seeking Alpha
- 2 months ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire
- 2 months ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 3 months ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga
- 3 months ago - CytoDyn Releases ESMO Breast Cancer Meeting Poster - GlobeNewsWire
- 3 months ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha
- 3 months ago - CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors - GlobeNewsWire